Healthcare Industry News: Terumo Medical
News Release - October 8, 2013
Terumo Interventional Systems Launches The Detachable AZUR(R) CX Peripheral Coil SystemThe First & Only Peripheral Coil Designed for Cross-Sectional Coverage Incorporating the Benefits of TerumoŽ Patented Hydrogel Technology
SOMERSET, N.J., Oct. 8, 2013 -- (Healthcare Sales & Marketing Network) -- Terumo Interventional Systems, a division of Terumo Medical Corporation, today announced the nationwide availability of the AZURŽ CX Peripheral Coil System (AZUR CX), the first and only peripheral embolization coil designed to provide cross-sectional coverage incorporating the benefits of Terumo's patented hydrogel technology. Terumo launched the AZUR CX at the 11th Vascular InterVentional Advances Conference (VIVA), October 8 to 11, in Las Vegas, NV.
The AZUR CX is an expansion of Terumo's AZURŽ family of embolization coils for endovascular occlusion of peripheral vessels. It has a unique coil construction with hydrogel on the inside for a soft, flexible design. The hydrogel technology creates a scaffold for neointimal growth formation and allows mechanical occlusion of the vessel with less reliance on thrombus for embolization. The AZUR CX creates a complex shape that enhances cross-sectional coverage by filling the vessel, leaving no gap in the center. It can be deployed with minimal catheter manipulation.
"Placing embolic coils in high-flow vessels is always a challenge, because of the possibility the coil will move after placement. Maintaining control is critical. From the first loop, the AZUR CX with hydrogel technology instills confidence, because it creates a stable anchor in the vessel," said Frank R. Arko III, MD, Sanger Heart and Vascular Institute, Carolinas Medical Center, Charlotte, North Carolina. "The coil has minimal preparation time and with the AZURŽ Detachment Controller I can achieve precise placement."
The U.S. market for peripheral vascular embolization coil procedures is expected to grow by approximately 5.8 percent annually through 20161. This increase is primarily driven by innovation in detachable coil technology and access devices, which allow physicians to treat a wider variety of patient conditions. Compared to traditional pushable embolic coils, detachable coils offer enhanced clinical benefits, including more precise positioning, that allow physicians to extend further into more tortuous anatomy, where distal embolization is a concern.
"The AZUR CX is a great addition to Terumo's diversified portfolio of peripheral embolization products. This device is yet another example of Terumo's commitment to satisfying the needs of physicians who treat patients in the emerging embolization market," said Chris Pearson, Vice President, Marketing, Terumo Interventional Systems. "Terumo's mission is to combine the right product solutions with high-quality training and education programs that help physicians deliver the highest level of clinical care."
For more information about the AZUR CX, visit www.terumois.com or connect to your local Terumo sales representative by calling 800-862-4143.
1 Total PV Embolization Procedures, by Indication, US, 2009-2016. Millennium Research: Combines Pushable & Detachable MKT
Terumo Interventional Systems
Terumo Interventional Systems (TIS), a division of Terumo Medical Corporation, is a market leader in minimally invasive entry site management and lesion access technologies. TIS offers a complete, solution-based product portfolio used in advanced coronary, peripheral endovascular and urological treatments with strategic initiatives in Transradial Access, Complex Coronary Intervention and Critical Limb Ischemia. TIS combines innovative research and development with a deep market understanding to create a pipeline of industry leading devices that deliver clinical value, economic benefit, and enhanced patient outcomes. Terumo Medical Corporation is part of Tokyo-based Terumo Corporation; one of the world's leading medical device manufacturers with $4 billion in sales and operations in more than 160 nations.
Source: Terumo Interventional Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.